SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Lab is trending following news of a Neutron Stage 1 tank rupture during qualification testing, sparking a heated debate among investors. While some view the incident as a critical setback signaling potential delays for the highly anticipated Neutron rocket, others maintain it's a routine de-risking event integral to advanced aerospace development. The conversation centers on the implications for the company's ambitious launch schedule and recent momentum in the space sector.

TMC the metals co., Inc. is a deep-sea minerals exploration company focused on the collection and processing of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone in the Pacific Ocean (CCZ). These nodules contain high grades of four metals (nickel, copper, cobalt, manganese) which can be used as (i) feedstock for battery cathode precursors (nickel, cobalt and manganese sulfates, or intermediate nickel-copper-cobalt matte) for electric vehicles (EV) and renewable energy storage markets, (ii) copper cathode for EV wiring, energy transmission and other applications and (iii) manganese silicate for manganese alloy production required for steel production. The company was founded in 2021 and is headquartered in Vancouver, Canada.

TMC the metals company Inc

TMC is trending as the community keenly watches significant regulatory developments, including modernized deep-sea mining permit processes from NOAA and an upcoming Congressional hearing featuring the CEO. This activity is fueled by a growing recognition of deep-sea minerals as a national security priority and strong market expectations for accelerated project timelines.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending due to significant insider buying, with CEO Ryan Cohen substantially increasing his stake over consecutive days, joined by another board member. This show of conviction is fueling community speculation about a potential short squeeze and a "bottom" being found, reminiscent of past meme stock events. Many are discussing this as a direct challenge to short sellers and a strategic move by management.

Venture Global, Inc. engages in the development and construction of liquefied natural gas production, establishing us as a rapidly growing company delivering critical LNG to the world. It projects include Calcasieu, Plaquemines, CP2, CP3 and Delta projects. The company was founded by Michael Sabel and Robert Pender in 2023 and is headquartered in Arlington, VA.

Venture Global Inc. - Ordinary Shares - Class A

Venture Global Inc

Venture Global is significantly trending after announcing a favorable arbitration award against Repsol, validating its operational conduct regarding Calcasieu Pass LNG sales. This pivotal win has fueled intense bullish sentiment, with the community actively discussing a potential substantial short squeeze and a strong stock rebound. Many foresee continued upside, driven by the company's execution and persistent global demand for LNG.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is experiencing a significant surge, driven by recent analyst upgrades, robust server CPU demand, and growing optimism for its advanced 18A process technology and Panther Lake processors. The community is actively discussing massive gains and long-term potential fueled by strategic government backing, though some anticipate a "sell the news" reaction as investors await the upcoming earnings report.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Fueling intense debate, Sandisk ($SNDK) is experiencing a historic surge, largely attributed to robust demand for memory and data storage driven by AI infrastructure and tight supply conditions. Community sentiment is bifurcated, with bulls reveling in its "unstoppable" trajectory and a potential short squeeze, while bears warn of an unsustainable "bubble" and impending correction given its extraordinary valuation.

PAVmed, Inc. is a multi-product life sciences company, which engages in the innovation, development, acquisition, and commercialization of products that target unmet medical needs with large addressable market opportunities. Its products include Lucid Diagnostics and Veris Health. The company was founded by Lishan Aklog and Brian J. deGuzman on June 26, 2014 and is headquartered in New York, NY.

PAVmed Inc

PAVmed is experiencing extreme volatility and a surge in trading volume following news that its subsidiary, Lucid Diagnostics, secured a significant contract with the U.S. Department of Veterans Affairs for its EsoGuard Esophageal DNA Test. This development, coupled with its notably low share float and recent reverse split, has ignited intense speculative trading, leading many to label it a prime short squeeze candidate. While some foresee substantial further gains, others remain cautious, warning of a potential pump and dump scenario amidst reports of heavy selling pressure.

Uniting the six native Japanese dog breeds. Kendu is the keeper of peace, the preserver of life, and the protector of unity. Join the pack!!

Kendu

KENDU CRYPTO is actively trending due to its community's relentless focus on building a permissionless brand with a diverse array of real-world products and initiatives, including Kendu Spice and Kendu Energy. The highly engaged community emphasizes continuous development across multiple blockchains, showcasing strong conviction for long-term growth and practical utility in the crypto space.

Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

Ardelyx is trending due to rumors of a potential acquisition by Zydus Lifesciences, amplified by recent positive updates including a significant patent extension to 2041 for its key therapies and bullish revenue guidance for IBSRELA. The community is actively discussing valuation, believing the company is fundamentally undervalued given its strengthened intellectual property and expanding market potential for its approved drugs.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna is experiencing significant upward momentum driven by robust five-year follow-up data from its personalized cancer vaccine study with Merck, signaling strong potential beyond its initial vaccine focus. The community is actively discussing the stock's perceived undervaluation and the potential for a substantial short squeeze, with many anticipating its oncology pipeline as a major future growth catalyst.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Biotech stocks remain a hot sector for retail traders on Stocktwits,&nbsp;which collectively boast over 3.45 million followers.&nbsp;In January, several biotech names saw explosive gains as investors bet on breakthrough treatments, key partnerships, and regulatory milestones.According to Stocktwits data, these five biotech stocks saw the highest surge in retail following this month.CARGO Therapeutics Inc. (CRGX) – 445% Jump In FollowersCARGO Therapeutics, a clinical-stage biotech company focused on cancer treatments, saw its stock collapse even as retail interest surged.&nbsp;In January, the FDA cleared its Investigational New Drug (IND) application for CRG-023, a novel tri-specific CAR T therapy designed to tackle relapse factors in B-cell malignancies.&nbsp;However, the company later announced it would discontinue a Phase II trial of its lead candidate, firi-cel, after an ad hoc safety analysis revealed an unfavorable benefit-risk profile.&nbsp;Wall Street analysts issued downgrades, and CARGO’s stock is on track to plunge more than 76% in January — its worst month since going public in November 2023.&nbsp;Short interest stands at 15.1%, according to Koyfin data.Sana Biotechnology Inc. (SANA) – 185% Jump In FollowersSana Biotechnology, which focuses on engineered cell therapies, captured investor attention with a potential&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sana-biotech-stock-triples-after-type-1-diabetes-trial-data/chGBWsVRZO">breakthrough</a> in type 1 diabetes.&nbsp;The company demonstrated earlier this month that its hypoimmune edits allowed islet cell transplant survival without immunosuppression.&nbsp;Analysts praised the findings, driving the stock up roughly 114% in January — its best month since its March 2021 market debut.&nbsp;Short interest is at 16.6%.Silexion Therapeutics Corp. (SLXN) – 92% Jump In FollowersSilexion, an oncology-focused biotech developing RNA interference therapies, gained momentum after releasing preclinical data on a second-generation siRNA candidate, SIL-204.&nbsp;The treatment&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/slxn-stock-hits-record-low-after-pricing-5m-offering/chGtwKoRng">showed</a> synergistic efficacy when combined with first-line chemotherapy for pancreatic cancer.&nbsp;Although the stock gained just 2% in January, it marked its best month since November.&nbsp;Short interest remains low at 2.4%.AEON Biopharma Inc. (AEON) – 81% Jump In FollowersAEON Biopharma is developing ABP-450, a botulinum toxin complex similar to Evolus’ Jeuveau, for medical indications such as chronic migraine.&nbsp;Retail traders appeared to buy the dip after AEON priced a $20 million public offering earlier this month, which initially sent shares tumbling.&nbsp;The stock is headed for a 77% drop in January, its worst month since going public via a SPAC merger in July 2023.&nbsp;Short interest is just 0.2%, according to Koyfin.Kairos Pharma (KAPA) – 78% Jump In FollowersKairos Pharma, a clinical-stage biopharmaceutical company, saw retail interest soar this month after breaking key resistance levels and securing crucial investments.&nbsp;The company is testing its lead candidate, ENV105 — which targets a protein linked to resistance in cancer treatments — in Phase 2 trials for castrate-resistant prostate cancer and Phase 1 trials for lung cancer.The stock gained momentum following CEO John Yu’s positive comments at an investor healthcare summit this month and the completion of a $3.5 million PIPE transaction.&nbsp;Kairos shares are set to decline 2.6% in January, marking their worst month since October.&nbsp;Short interest remains&nbsp;negligible at 0.1%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Hand holding test tube over stock data on computer monitor. | Image source: Getty Images

Retail Traders Flocked To These 5 Biotech Stocks In January — Here’s Why

Biotech remains a high-risk, high-reward sector, and this month’s top draws reflect retail’s appetite for stocks with major clinical and regulatory catalysts.

Equity

Biotech remains a high-risk, high-reward sector, and this month’s top draws reflect retail’s appetite for stocks with major clinical and regulatory catalysts.


Three nano-cap healthcare stocks drew massive attention from retail investors on Stocktwits Tuesday, though not all for positive reasons.Trinity Biotech (<a href="https://stocktwits.com/symbol/TRIB">TRIB</a>)&nbsp;Shares of the medical diagnostic products maker saw a staggering 15,550% jump in retail message volume after the company released “compelling” results from a study on its next-generation continuous glucose monitoring system.&nbsp;The device, designed for real-time diabetes management, demonstrated superior signal quality, accuracy, and consistency in a trial involving 30 diabetic participants.&nbsp;The system features a reusable applicator and rechargeable wearable transmitter, reducing costs by eliminating disposable components.&nbsp;Trinity said it remains on track to seek regulatory approval in the EU by 2025 and the U.S. by 2026.&nbsp;Shares fell over 13% premarket Wednesday.Silexion Therapeutics (<a href="https://stocktwits.com/symbol/SLXN">SLXN</a>)&nbsp;The cancer-focused biotech firm’s ticker saw a 9,060% surge in retail message volume as its stock more than doubled Tuesday following promising preclinical data for its tumor drug candidate SIL-204.&nbsp;The company reported that the extended-release formulation of SIL-204 reduced tumor growth by more than 50% after 30 days, with around 50% of tumors showing complete necrosis in human pancreatic models.&nbsp;Additionally, an injectable version of the drug candidate showed tumor growth inhibition in metastatic pancreatic mouse models.&nbsp;The stock continued its rally, gaining over 70% premarket Wednesday.Sharps Technology (<a href="https://stocktwits.com/symbol/STSS">STSS</a>)&nbsp;The medical packaging firm experienced a 6,233% surge in retail message volume, but for the wrong reasons.&nbsp;Shares plunged nearly 70% to a record low on Tuesday after the company announced a $20 million public offering of 14,285,714 Common Units.&nbsp;Each unit consists of one share of common stock, one Series A warrant, and one Series B warrant, priced at $1.40 per unit, a 4.1% discount to Monday’s close.&nbsp;The company said the proceeds would be used for general corporate purposes and working capital.&nbsp;The stock continued to slide, down over 2% premarket Wednesday.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stockbroker analyzing financial stock market with reflection on eyeglasses. Photo via Westend61 on Getty Images

TRIB, SLXN, STSS: Why Retail Chatter On 3 Nano-Cap Healthcare Stocks Exploded Over 6000%

“Compelling” results from a study, promising pre-clinical data and a public offering got Stocktwits investors buzzing on Tuesday.

Shares of Silexion Therapeutics lost&nbsp;more than a quarter of their market capitalization on Thursday morning, hitting a record intraday low after the company priced a $5 million public offering late Wednesday.The stock is also on track for its worst day since Dec. 26.The offering includes approximately 3.7 million ordinary shares and accompanying warrants for&nbsp;purchasing up to 3.7 million additional shares.&nbsp;Priced at $1.35 per share and warrant, the offering was below Wednesday’s closing price of $1.56.&nbsp;The warrants, which will expire five years from issuance, carry an exercise price of $1.35 and are exercisable immediately. The offering is expected to close on Friday.<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/SLXN_sentiment_and_message_volume_Jan_16_ebe16b64bc.png" alt="SLXN sentiment and message volume Jan 16.png" width="1318" height="324"><figcaption>SLXN sentiment and message volume Jan 16 as of 10 am ET | source: Stocktwits</figcaption></figure>Despite the steep decline in share price, retail sentiment for Silexion was ‘extremely bullish’ on Stocktwits, where message volume surged to a six-month high.&nbsp;Some users voiced plans to buy shares once the offering concludes, while others noted the company’s low float, available cash, and technical levels as reasons for cautious optimism.<stembedurl>https://stocktwits.com/Kevin_Gough/message/600264740</stembedurl><stembedurl>https://stocktwits.com/Patience__/message/600239429</stembedurl><stembedurl>https://stocktwits.com/StockProphercy/message/600293377</stembedurl>Fueling this sentiment further is Wednesday’s release of encouraging preclinical data for Silexion’s experimental pancreatic cancer treatment, SIL-204.&nbsp;According to the company, SIL-204 demonstrated strong synergistic effects when combined with common chemotherapeutic agents, including 5-fluorouracil, irinotecan, and gemcitabine, in human cell lines with KRAS G12D mutations, the most prevalent type of pancreatic cancer.Silexion said it plans to initiate toxicology studies for SIL-204 within the next few months, with phase 2/3 clinical trials scheduled for the first half of 2026.&nbsp;Financially, Silexion ended the third quarter of 2024 with cash and equivalents totaling $2 million and debt near $230,000, according to Koyfin.&nbsp;However, the stock has lost over 98% of its value in the past year, reflecting challenges that may&nbsp;affect its prospects.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Silexion Stock Hits Record Intraday Low After Pricing $5M Offering, But Retail Excitement Over Cancer Data Endures

Priced at $1.35 per share and warrant, the offering was below Wednesday’s closing price of $1.56.

The market’s resilience came under test on Wednesday as apprehensions ahead of earnings from artificial intelligence stalwart Nvidia Corp. (<a class="mention" data-mention="$NVDA" data-symbol-id="NVDA" href="https://stocktwits.com/symbol/NVDA" target="_blank">$NVDA</a>) generated some weakness early in the session.Nvidia stock was last seen trading down more than 1%, giving back some of the nearly 5% gain it made on Wednesday.As traders look ahead to the company’s market-moving&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ai-stalwart-nvidia-to-report-q3-2025-results-wednesday/cJ4UNCxRQC">earnings report,</a> due after the market close, here is a compilation of the most bullish stocks on Stocktwits:Forte Biosciences, In. (<a class="mention" data-mention="$FBRX" data-symbol-id="FBRX" href="https://stocktwits.com/symbol/FBRX" target="_blank">$FBRX</a>)&nbsp;Forte Biosciences shares were last seen rallying over 170% as the nano-cap autoimmune disorders-focused clinical-stage biopharma said its equity financing to support the continuing clinical advancement of its lead candidate FB102 was oversubscribed. “ As a result of the financing, Forte is well capitalized to continue advancing FB102 across autoimmune indications,” it added.Quantum-Si Inc. (<a class="mention" data-mention="$QSI" data-symbol-id="QSI" href="https://stocktwits.com/symbol/QSI" target="_blank">$QSI</a>):Shares of Quantum-Si, a medical-device company that develops a single-molecule detection platform to enable next-gen protein sequencing (NGPS), more than doubled on Wednesday on volumes that are notably above their 3-month average.The upside came after the company made a slew of announcements. Quantum-Si said Avantor, Inc. (<a class="mention" data-mention="$AVTR" data-symbol-id="AVTR" href="https://stocktwits.com/symbol/AVTR" target="_blank">$AVTR</a>) will distribute its NGPS portfolio, providing researchers across the U.S. and Canada access to the portfolio.In a separate release, Quantum-Si announced a collaboration with Nvidia to develop its next proteomics platform called Proteus and advance its core technologies of amino acid binders and amino peptidases using Nvidia AI and accelerated computing.&nbsp;Quantum-Si also announced an expanded partnership with SkyWater Technology, Inc. (<a class="mention" data-mention="$SKYT" data-symbol-id="SKYT" href="https://stocktwits.com/symbol/SKYT" target="_blank">$SKYT</a>) for developing Proetus and a separate deal with its contract manufacturing partner Planet Innovation for the same.&nbsp;Silexion Therapeutics Corp. (<a class="mention" data-mention="$SLXN" data-symbol-id="SLXN" href="https://stocktwits.com/symbol/SLXN" target="_blank">$SLXN</a>)Silexion, a clinical-stage biotech developing RNA interference therapies for certain types of cancers, disclosed in a filing on Tuesday that at the reconvened extraordinary general meeting, its shareholders approved the board recommendation for a reverse split of the shares in the ratio 1-for-9.&nbsp;The penny stock climbed 33% on Wednesday on above-average volume.Duos Technologies Group, Inc. (<a class="mention" data-mention="$DUOT" data-symbol-id="DUOT" href="https://stocktwits.com/symbol/DUOT" target="_blank">$DUOT</a>)Shares of Jacksonville, Florida-based Duos Tech, a software services provider, climbed over 17% after the company announced the signing of a $42 million worth of asset management agreement with Fortress Investment Group to deploy and operate a fleet of mobile gas turbines and balance-of-plant inventory that has a combined generation capacity of 850 megawatts.ZIM Integrated Shipping Services Ltd. (<a class="mention" data-mention="$ZIM" data-symbol-id="ZIM" href="https://stocktwits.com/symbol/ZIM" target="_blank">$ZIM</a>)Cargo shipping firm ZIM Integrated reported <a href="https://stocktwits.com/news-articles/markets/equity/zim-integrated-shipping-stock-rises-premarket-after-strong-q3-earnings/cJ46SQoRXc">upbeat third-quarter earnings</a> and raised its full-year guidance, sending its shares higher by over 7%. Retail hoped for large buyers increasing their exposure to the stock, sending it to the $31-$32 area by the close.<stembedurl>https://stocktwits.com/View2021/message/593365202</stembedurl>For updates and corrections email <a target="_blank" rel="noopener noreferrer nofollow" href="mailto:newsroom@stocktwits.com">newsroom@stocktwits.com</a>&nbsp;Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/nvidia-q3-2025-earnings-imminent/cJ46Z2LRXE">Nvidia Stock Slips Ahead Of Earnings: Gene Munster Explains Why Blackwell Chip Demand Commentary Is Important For Investors</a>

US Stocks dipped ahead of Nvidia earnings but a few sent retailers into a tizzy. 

5 Stocks Retail Investors Are Most Bullish On At Mid-Day

Retailers went overboard about a couple of biotech stocks and a MedTech name, among others on Wednesday.

Silexion Therapeutics Corp. is a clinical-stage biotechnology company, which engages in the discovery and development of treatments for KRAS-driven cancers. The company was founded on November 30, 2008 and is headquartered in in Modiin, Israel.

Silexion Therapeutics Corp

Up 10% or more

0% to up 9%

Down 1% to 9%

Down 10% or more

The S&P 500 enters 2026 after a strong run. What kind of return do you expect this year?

How will the S&amp;P 500 perform in 2026?

Current Price	$2.11
Prev Close	$2.24
Open	$2.27
Dividend Yield	0.00%
50-Day Moving Average	$2.49
Beta	1.09
Avg. Volume	55,053.77
PE Ratio	-0.08

52-Week High	$51.75
52-Week Low	$1.65
Market Capitalization	$7M
EPS (Annual)	-$395.36
Price to Book	0.95
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

SLXN
Silexion Therapeutics Ltd

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest SLXN News

SLXNSilexion Therapeutics Ltd